Published in Ann Hematol on March 01, 1992
Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol (1998) 1.55
Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol (2010) 1.08
Novel immunotherapies. Cancer J (2009) 0.82
CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance. J Clin Pathol (1995) 0.81
The development of potential antibody-based therapies for myeloma. Blood Rev (2014) 0.81
An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells. Diagn Pathol (2012) 0.78
Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1). J Clin Pathol (1998) 0.78
Immuno-targeting the multifunctional CD38 using nanobody. Sci Rep (2016) 0.77
New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology. Mol Cell Oncol (2015) 0.76
Immunotherapies targeting CD38 in Multiple Myeloma. Oncoimmunology (2016) 0.75
Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity. J Immunol (2017) 0.75
Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity (1996) 2.96
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med (1991) 2.58
Diffusion-weighted MR imaging of bone marrow: differentiation of benign versus pathologic compression fractures. Radiology (1998) 2.51
Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol (1988) 1.96
Clinical and epidemiologic features of infection with Mycobacterium genavense. Swiss HIV Cohort Study. Arch Intern Med (1995) 1.95
Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood (2000) 1.90
Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRgamma chain. J Biol Chem (2000) 1.82
UV-induced skin changes due to regular use of commercial sunbeds. Photodermatol Photoimmunol Photomed (2002) 1.81
Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.62
Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol (1987) 1.56
Positron emission tomography in neuropsychiatric lupus erythematosus. Neurology (1990) 1.52
Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol (1998) 1.49
Systemic scleroderma. Multicenter trial of 1 year of treatment with recombinant interferon gamma. Arch Dermatol (1997) 1.49
Cervical spine: postmortem assessment of accident injuries--comparison of radiographic, MR imaging, anatomic, and pathologic findings. Radiology (2001) 1.48
Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res (1997) 1.42
FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood (1998) 1.40
The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) (2008) 1.32
Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J Immunol (1999) 1.31
Assessment of bone marrow histology in Hodgkin's disease: correlation with clinical factors. Br J Haematol (1982) 1.30
Acute systemic reaction and lung alterations induced by an antiplatelet integrin gpIIb/IIIa antibody in mice. Blood (1999) 1.25
Distinct tissue site-specific requirements of mast cells and complement components C3/C5a receptor in IgG immune complex-induced injury of skin and lung. J Immunol (2001) 1.24
Lymphoproliferations in the bone marrow: identification and evolution, classification and staging. J Clin Pathol (1984) 1.24
High local interleukin 5 production in granuloma faciale (eosinophilicum): role of clonally expanded skin-specific CD4+ cells. Br J Dermatol (2005) 1.23
The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol (1990) 1.18
Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int (1988) 1.18
A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction. J Immunol (2000) 1.17
Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. AJR Am J Roentgenol (1996) 1.14
Emergence and decay of the human Mx homolog in cancer patients during and after interferon-alpha therapy. J Biol Response Mod (1990) 1.14
Bone formation in coralline hydroxyapatite. Effects of pore size studied in rabbits. Acta Orthop Scand (1994) 1.13
Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol (1997) 1.13
Solubilization and characterization of surface antigenic components of Erysipelothrix rhusiopathiae T28. Infect Immun (1986) 1.09
Testing for association in SLE families. Genet Epidemiol (1991) 1.07
Fc gamma RIII-mediated production of TNF-alpha induces immune complex alveolitis independently of CXC chemokine generation. J Immunol (2001) 1.06
Intrinsic human glomerular mesangial cells can express receptors for IgG complexes (hFc gamma RIII-A) and the associated Fc epsilon RI gamma-chain. J Immunol (1994) 1.05
On the role of complement and Fc gamma-receptors in the Arthus reaction. Mol Immunol (2000) 1.05
Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet (1987) 1.04
Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer (2011) 1.04
Mouse FcgammaRII is a negative regulator of FcgammaRIII in IgG immune complex-triggered inflammation but not in autoantibody-induced hemolysis. Eur J Immunol (2000) 1.04
MX homologous protein in mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum (1989) 1.04
Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer (1988) 1.03
A PEG-precipitation laser nephelometer technique for detection and characterization of circulating immune complexes in human sera. J Immunol Methods (1982) 1.03
Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol (2001) 1.03
[Haptoglobin "Marburg"; studies on a rare hereditary haptoglobin variant with 2 different phenotypes in one family]. Humangenetik (1965) 1.03
Bias of culture techniques for diagnosing mixed Mycobacterium genavense and Mycobacterium avium infection in AIDS. J Clin Microbiol (1994) 1.02
Cutting edge: Fc receptor type I for IgG on macrophages and complement mediate the inflammatory response in immune complex peritonitis. J Immunol (1999) 1.01
In vitro modulation of human melanoma cell invasion and proliferation by all-trans-retinoic acid. Melanoma Res (1998) 1.00
Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. J Drugs Dermatol (2006) 1.00
IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. SLE Study Group. Rheumatol Int (1998) 1.00
[Rehabilitation in geriatric patients after ischemic stroke--a comparison of 2 organisational systems in Germany using claims data of a statutory health insurance fund]. Rehabilitation (Stuttg) (2013) 1.00
In vitro immunoglobulin production by peripheral blood mononuclear cells from multiple myeloma patients and patients with benign monoclonal gammopathy. Regulation by cell subsets. Scand J Immunol (1984) 1.00
Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol (1999) 1.00
Bone biopsy in haematological disorders. J Clin Pathol (1982) 1.00
Idiotype-bearing peripheral blood lymphocytes in human multiple myeloma and Waldenström's macroglobulinaemia. Scand J Immunol (1980) 0.99
Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem (1996) 0.99
Leucocyte-migration test in sarcoidosis. Lancet (1972) 0.98
Inhibition of fibroblast chemotaxis by superoxide dismutase. Eur J Cell Biol (1987) 0.98
In vitro production of monoclonal and polyclonal immunoglobulins by peripheral blood mononuclear cells in human plasma cell myeloma. Scand J Immunol (1982) 0.98
The IgG binding site of human FcgammaRIIIB receptor involves CC' and FG loops of the membrane-proximal domain. J Biol Chem (1996) 0.97
Serotonin content of platelets in inflammatory rheumatic diseases. Correlation with clinical activity. Arthritis Rheum (1983) 0.96
In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers. J Pathol (1999) 0.96
Rapid expression of the CD69 antigen on T cells and natural killer cells upon antigenic stimulation of peripheral blood mononuclear cell suspensions. Allergy (1997) 0.95
Evaluation of early diagnostic criteria for ankylosing spondylitis in a 10 year follow-up. Z Rheumatol (1990) 0.95
Circulating immune complexes in ankylosing spondylitis. Br J Rheumatol (1983) 0.95
MRI gadolinium enhancement of bone marrow: age-related changes in normals and in diffuse neoplastic infiltration. Skeletal Radiol (1997) 0.94
The interferon-induced Mx-homologous protein in people with symptomatic HIV-1 infection. AIDS (1990) 0.94
An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia (2004) 0.94
MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Rheumatology (Oxford) (1999) 0.94
MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res (2001) 0.94
Linear spiradenoma with focal malignant transformation. J Eur Acad Dermatol Venereol (2003) 0.94
Platelet aggregation and aggregation inhibition by different antiglobulins and antiglobulin complexes from sera of patients with rheumatoid arthritis. Arthritis Rheum (1979) 0.93
Activation of cloned human natural killer cells via Fc gamma RIII. J Immunol (1989) 0.93
Autonomic and sensorimotor neuropathy in patients with systemic lupus erythematosus and systemic sclerosis. J Rheumatol (1996) 0.92
Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res (2001) 0.92
Chronic myeloproliferative disorders (CMPD). Pathol Res Pract (1984) 0.92
Effect of eledoisin on tear volume and tear flow in humans as assessed by fluorophotometry. Graefes Arch Clin Exp Ophthalmol (1991) 0.92
IFN-gamma induces the high-affinity Fc receptor I for IgG (CD64) on human glomerular mesangial cells. Eur J Immunol (1998) 0.91
Karyotype in multiple myeloma and plasma cell leukaemia. Eur J Cancer (1993) 0.91
The genetic basis of Ro and La antibody formation in systemic lupus erythematosus. Results of a multicenter study. The SLE Study Group. Rheumatol Int (1992) 0.91
T cells in monoclonal gammopathies. Scand J Haematol (1982) 0.91
[Suppression of transplantation reaction by a new nitrogen mustard compound, 3-(2-chlorethyl)-2-(2-chlorethylamino)-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide]. Arzneimittelforschung (1970) 0.91
Palliative radiotherapy in plasma cell myeloma. Radiother Oncol (1991) 0.90
Histologic classification and staging of chronic lymphocytic leukemia. A retrospective and prospective study of 503 cases. Acta Haematol (1988) 0.90
Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int (1985) 0.89
Cutaneous pseudolymphoma arising after tattoo placement. J Eur Acad Dermatol Venereol (2007) 0.89
Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol (1982) 0.89
Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study. Br J Dermatol (2009) 0.89
Mast cells induce autoantibody-mediated vasculitis syndrome through tumor necrosis factor production upon triggering Fcgamma receptors. Blood (1999) 0.88
A possible new incoherent lamp for photodynamic treatment of superficial skin lesions. Acta Derm Venereol (1994) 0.88
Fc gamma RIII activation is different in CD16+ cytotoxic T lymphocytes and natural killer cells. Eur J Immunol (1992) 0.87
High incidence of monoclonal immunoglobulins in patients after liver or heart transplantation. Transplantation (1988) 0.87
A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer (1995) 0.87
A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplant (2003) 0.87
[Immunologic analysis of the relation between the 3 types of antigen determinants of normal human haptoglobin]. Humangenetik (1966) 0.87